US2013053570A1PendingUtilityA1
CGRP Receptor Antagonists
Est. expiryOct 14, 2029(~3.2 yrs left)· nominal 20-yr term from priority
A61P 9/00A61P 43/00A61P 29/00A61P 25/06A61P 25/00A61P 15/12A61P 11/06A61P 11/00C07D 401/14A61K 31/4745C07D 471/10A61K 31/454C07D 401/12C07D 471/04C07D 471/20A61K 31/437
50
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The disclosure generally relates to the novel compounds of formula I, including pharmaceutically acceptable salts, which are CGRP receptor antagonists. The disclosure also relates to pharmaceutical compositions and methods for using the compounds in the treatment of CGRP related disorders including migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases such as asthma, and chronic obstructive pulmonary disease (COPD).
Claims
exact text as granted — not AI-modified1 . The compound (6R,9R)-6-(2,3-Difluorophenyl)-6-hydroxy-5-oxo-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate or a pharmaceutically acceptable salt thereof.
Join the waitlist — get patent alerts
Track US2013053570A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.